

**PRESS RELEASE**

## **Cure51 Joins Worldwide Innovative Network (WIN) in Personalized Cancer Medicine Consortium - WIN Consortium**

November 12, 2024 - Cure51 and Worldwide Innovative Network (WIN), in personalized cancer medicine consortium have joined forces to bring cancer research to a new level, rallying the brightest oncologists, and academics in the world and leveraging data, cutting edge precision tech to make cancer a disease of the past. WIN Consortium is a network of 39 world-class academic medical centers, industries, research organizations and patient advocates spanning 19 countries and 5 continents.

*“We are excited to welcome Cure51 to WIN and we look forward to working with their focused, inspired and dynamic teams,”* said **Prof. Wafik S. El-Deiry, Chair of WIN Consortium**, and Director, Legorreta Cancer Center, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University.

*“Investigating exceptional cancer survivors is a brilliant idea and WIN network can contribute to this endeavor with our global footprint,”* said **Dr Razelle Kurzrock, Chief Medical Officer of WIN**, Professor of Medicine, Associate Director Clinical Research, MCW Cancer Center and Linda T. & John A. Mellowes Chair of Precision Oncology.

*“We are on a tireless mission to impact cancer in the next 10 years, and the partnership with WIN is a huge step in the right direction,”* says **Cure51 co-founder Simon Istolainen**, *“We believe that cancer is a disease of the past, and with the best medical institutes in the world, we are building the tech to prove it. In a matter of years, we want every patient to become a miraculous survivor. Today, depending on the type of cancer 0.5% to 2% of patients survive aggressive cancers; we’re building a database of survivors to crack the survival code, which we know exists in nature, and drastically increase this ratio”*.

---

### **About WIN Consortium**

WIN Consortium is a non-profit association headquartered in France. WIN was the first consortium that assembled all stakeholders of cancer care, from academia, industry, and patient advocates to work together across the globe. The WIN network assembles 39 world-class academic medical centers, industries, research organizations and patient advocates spanning 19 countries and 5 continents, aligned to launch trials to bolster Precision Oncology across the world. It was also the first organization to launch a N-of-One study using transcriptomics in addition to genomics to inform therapeutic choice in the WINTHER study

WIN is the organizer of the WIN symposia in Precision Oncology.

### **About Cure 51**

Cure51 is a French 'TechBio' company founded by Nicolas Wolikow and Simon Istolainen, alongside seasoned entrepreneurs and five world-renowned oncology centres: Gustave Roussy Cancer Campus (IGR, Paris - France), Leon Bérard Center (CLB, Lyon - France), Charité Universitätsmedizin (Berlin - Germany), and Vall d'Hebron (VHIO, Barcelona - Spain). The collaboration between the private and public sectors is at the core of the Cure51 project, led by a passionate team with expertise in computing, medicine, and biology, and partnered with principal investigators across its network of over 50 leading oncology centres worldwide.

Cure51's exclusive data collection system, based on partnerships, enables the creation of a unique multimodal and multiomics database of Outliers. Using its discovery platform powered by computational modeling, Cure51 aims to understand the biological mechanisms responsible for this exceptional survival by identifying and validating targets that can act on these interactions, leading to first in class treatments. This research involves the use of all relevant models (in silico, in vitro, in vivo, ex vivo) and the integration of existing literature and available databases, along with the engagement of Cure51's KOL community. Ultimately, drug design will be subject to collaboration contracts with the industry. Further information can be found at [www.cure51.com](http://www.cure51.com)

### **Contacts**

#### **WIN Consortium**

[www.winconsortium.org](http://www.winconsortium.org)

Catherine Bresson, Director Operational Team

[catherine.bresson@winconsortium.org](mailto:catherine.bresson@winconsortium.org)

#### **Cure51**

[www.cure51.com](http://www.cure51.com)

Clara Armand-Delille

[clara@thirdeyemedia.press](mailto:clara@thirdeyemedia.press)